Literature DB >> 10496275

The clinical course of neuromyelitis optica (Devic's syndrome).

D M Wingerchuk1, W F Hogancamp, P C O'Brien, B G Weinshenker.   

Abstract

OBJECTIVES: To evaluate the spectrum of neuromyelitis optica (NMO), including characteristics of the index events (optic neuritis [ON]) and myelitis), neuroimaging, CSF, and serologic studies, and to evaluate the long-term course.
METHODS: Review of 71 patients with NMO evaluated at the Mayo Clinic between 1950 and 1997.
RESULTS: NMO was either monophasic or relapsing. Patients with a monophasic course (n = 23) usually presented with rapidly sequential index events (median 5 days) with moderate recovery. Most with a relapsing course (n = 48) had an extended interval between index events (median 166 days) followed within 3 years by clusters of severe relapses isolated to the optic nerves and spinal cord. Most relapsing patients developed severe disability in a stepwise manner, and one-third died because of respiratory failure. Features of NMO distinct from "typical" MS included >50 cells/mm3 in CSF (often polymorphonuclear), normal initial brain MRI, and lesions extending over three or more vertebral segments on spinal cord MRI.
CONCLUSIONS: Clinical, laboratory, and imaging features generally distinguish neuromyelitis optica from MS. Patients with relapsing optic neuritis and myelitis may have neuromyelitis optica rather than MS. Patients with a relapsing course of neuromyelitis optica have a poor prognosis and frequently develop respiratory failure during attacks of cervical myelitis.

Entities:  

Mesh:

Year:  1999        PMID: 10496275     DOI: 10.1212/wnl.53.5.1107

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  408 in total

1.  Eugène Devic (1858-1930).

Authors:  Isabelle Miyazawa; Kazuo Fujihara; Yasuto Itoyama
Journal:  J Neurol       Date:  2002-03       Impact factor: 4.849

Review 2.  A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis.

Authors:  Christopher Eckstein; Shiv Saidha; Michael Levy
Journal:  J Neurol       Date:  2011-09-20       Impact factor: 4.849

Review 3.  Optical coherence tomography (OCT): imaging the visual pathway as a model for neurodegeneration.

Authors:  Kristin M Galetta; Peter A Calabresi; Elliot M Frohman; Laura J Balcer
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

4.  Childhood multiple sclerosis and related disorders.

Authors:  Amna Al-Futaisi
Journal:  Oman Med J       Date:  2007-10

Review 5.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

6.  Effects of age and sex on aquaporin-4 autoimmunity.

Authors:  Amy M L Quek; Andrew McKeon; Vanda A Lennon; Jayawant N Mandrekar; Raffaele Iorio; Yujuan Jiao; Chiara Costanzi; Brian G Weinshenker; Dean M Wingerchuk; Claudia F Lucchinetti; Elizabeth A Shuster; Sean J Pittock
Journal:  Arch Neurol       Date:  2012-08

Review 7.  Aquaporin 4 and neuromyelitis optica.

Authors:  Marios C Papadopoulos; A S Verkman
Journal:  Lancet Neurol       Date:  2012-05-16       Impact factor: 44.182

8.  Optic neuromyelitis syndrome in Brazilian patients.

Authors:  R M Papais-Alvarenga; C M Miranda-Santos; M Puccioni-Sohler; A M V de Almeida; S Oliveira; C A Basilio De Oliveira; H Alvarenga; C M Poser
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-10       Impact factor: 10.154

9.  Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production.

Authors:  Elizabeth Cotzomi; Panos Stathopoulos; Casey S Lee; Alanna M Ritchie; John N Soltys; Fabien R Delmotte; Tyler Oe; Joel Sng; Ruoyi Jiang; Anthony K Ma; Jason A Vander Heiden; Steven H Kleinstein; Michael Levy; Jeffrey L Bennett; Eric Meffre; Kevin C O'Connor
Journal:  Brain       Date:  2019-06-01       Impact factor: 13.501

10.  The history of neuromyelitis optica.

Authors:  Sven Jarius; Brigitte Wildemann
Journal:  J Neuroinflammation       Date:  2013-01-15       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.